Navigation Links
Medicinal chemist wins inaugural De Burgh Fellowship
Date:11/11/2010

Medicinal chemist Dr Guillaume Lessene has been awarded the Walter and Eliza Hall Institute's inaugural de Burgh Fellowship at the institute's annual general meeting in Melbourne, Australia.

The $AUD150,000 de Burgh Fellowship honours the role Professor Patrick de Burgh played in shaping the Walter and Eliza Hall Institute. It was established this year following the death of Professor de Burgh in August at the age of 94.

It was in Professor de Burgh's laboratory at the University of Sydney that institute legends Professor Donald Metcalf, Professor Jacques Miller and Sir Gustav Nossal obtained their first taste of research.

Professor de Burgh was a Bosch Professor or Bacteriology at the University of Sydney and worked on the pathogenesis of infectious disease.

Dr Lessene said it was a great honour to be named the de Burgh Fellow. "The fact the fellowship acknowledges translational research is really important that is what I do every day and it's great that these activities are supported by the fellowship and the institute," Dr Lessene said.

Dr Lessene translates research findings from the institute into the discovery and development of new drugs. His main focus is cancer research and Dr Lessene is currently working on developing inhibitors to the pro-survival Bcl-2 proteins that are involved in programmed cell death, for treatment of several types of cancer. He is also involved in projects looking at other cancer targets, such as tyrosine kinases, and non-cancer targets involved in conditions such as Alzheimer's disease.

"We work in multidisciplinary teams in constant interaction with biologists to create small molecules that will interact with or modulate recognised cell signaling pathways or targets involved in disease, with the aim of treating or curing that disease," Dr Lessene said.

"The very high standing of the research at the institute is a key element in the success of our program. The Chemical Biology division of which I am part is there to take the next step, bringing these biological discoveries from the laboratory and translating them into molecules that have the right biological activities and properties to reach clinical trials and potentially become a new drug."

Institute director Professor Doug Hilton congratulated Dr Lessene and said the institute and the Australian community owed Professor de Burgh a great debt.

"One could only imagine the shape of Australian medical research today had Professor de Burgh provided a humdrum rather than an inspiring environment," Professor Hilton said.

"The De Burgh Fellowship is awarded to a scientist with an outstanding record of research or research translation, who collaborates productively with other members of the faculty, and who is likely to make a major contribution to the institute in the long term. Guillaume meets all these criteria with aplomb."


'/>"/>

Contact: Penny Fannin
fannin@wehi.edu.au
61-393-452-345
Walter and Eliza Hall Institute
Source:Eurekalert  

Related medicine news :

1. Medicinal cannabis review highlights dilemmas facing health care professionals
2. Pfizer joins open-access medicinal chemistry public-private collaboration
3. St. Johns wort collection mined for its medicinal value
4. MIT chemists engineer plants to produce new drugs
5. 2010 Chemistry Nobel laureate Ei-ichi Negishi leads C&EN webinar
6. Biochemist studies DNA repair with $787,000 in grants
7. MIT moves toward greener chemistry
8. Basque researchers apply chemistry to restoration of paintings and dating of signatures
9. Subtyping breast cancer by immunohistochemistry to investigate survival terms
10. Tastier MRE: Chemistry gives battlefield chow a gourmet flare
11. Dalton Pharma Services and Boehringer Ingelheim (Canada) Ltd. Announce the Renewal of their Chemistry Services Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Medicinal chemist wins inaugural De Burgh Fellowship
(Date:10/13/2017)... ... 2017 , ... The American Board of Family Medicine's (ABFM) Board of Directors ... Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. Newton will serve in ... retirement at the end of 2018. Upon assuming the role of President and CEO ...
(Date:10/13/2017)... , ... October 13, 2017 ... ... of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ... on guideline updates for the primary prevention of cardiovascular diseases during the ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Many families ... However, many long-term care insurance companies have a waiver for care if the client ... elimination period, when the family pays for care, is often waived, so the benefits ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in agile ... a contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise ... use of Agile methodologies in a consistent and high value manner across CMS ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... LAWRENCE, Mass. , Oct. 4, 2017 /PRNewswire/ ... developer of single-use, self-contained, illuminating medical devices, today ... National Health Surveillance Agency (or Agência Nacional ... ®. The first single-use, cordless surgical retractor with ... ONETRAC provides optimal access, illumination and exposure of ...
(Date:10/2/2017)... Oct. 2, 2017  Eli Lilly and Company (NYSE: ... for the third quarter of 2017 on Tuesday, October ... on that day with the investment community and media ... The conference call will begin at 9 a.m. Eastern ... a live webcast of the conference call through a ...
(Date:10/2/2017)... Halo Labs announces the European launch of their new low volume, ... 2017 in Cambridge, U.K on October 4th. ... samples with unprecedented speed and sensitivity while using far less sample ... ... system ...
Breaking Medicine Technology: